Slide 1: Delivering the Power of Sight Investor Presentation
Delivering the Power of Sight Investor Presentation August 2022 ™
Slide 2: Forward Looking Statements
1 Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act
Slide 3: Our Mission
2 Transform Ophthalmology and Optometry through products that target the underlying causes of the world’s most prevalent eye diseases Establish new treatment paradigms and create an interventional mindset in Eyecare to replace conventional outdated approaches Our Mission Goal: Products that Restore
Slide 4: Current Product Portfolio
CURRENT PRODUCT PORTFOLIO Additional products in development to build comprehensive portfolio of POAG and DED treatment options Glaucoma is #1 cause of irreversible blindness Microinvasive Glaucoma Surgery (MIGS) is the leading innovation in POAG treatment Underdeveloped Standalone MIGS segment repr
Slide 5: Strategic Value Creation Initiatives
Strategic Value Creation Initiatives Expand Presence in Established Combination Cataract MIGS Segment in POAG Continue gaining adoption among existing base of >5,600 MIGS-trained surgeons Continue penetrating Combination Cataract segment by leveraging the ability of OMNI® to address all three points
Slide 6: Surgical Glaucoma
SIGHT SCIENCES” () SURGICAL GLAUCOMA
Slide 7: OMNI: Leading Indication for Use for Both Combination Cataract and Standalone MIGS
5 OMNI: Leading Indication for Use for Both Combination Cataract and Standalone MIGS OMNI enables two sequential, ab interno MIGS procedures up to 360° each in adults with POAG – intuitive, minimally invasive, performed through a single clear corneal microincision Trabeculotomy using OMNI Canaloplas
Slide 8: OMNI: Comprehensive Mechanisms of Action
We believe (i) there is NO diagnostic to determine where the resistance is in the conventional outflow pathway and (ii) OMNI® is singularly well-suited to address all 3 primary points of resistance OMNI®: Comprehensive Mechanisms of Action TRABECULAR MESHWORK SCHLEMM’S CANAL COLLECTOR CHANNELS Trabe
Slide 9: Bladeless Goniotomy (SION)
19 Designed in-house; microengineered & precision-manufactured using specialized lasers 7 Fully meets AAO definition of goniotomy, aligns with Category I CPT code 65820 Innovative design bladelessly excises diseased trabecular meshwork across several clock-hours Targeting specific subsets of combina
Slide 10: Enabling an Interventional Mindset in POAG
Enabling an Interventional Mindset in POAG PRESCRIPTION MEDICATIONS Surgeons can use OMNI® to intervene across a broad population of POAG patients STANDALONE (>85%1 of POAG; ~5.4M eyes) COMBINATION CATARACT (<15%1; ~0.8M eyes) CONVENTIONAL TREATMENTS TRABECULAR BYPASS STENTS LASER TRABECULOPLASTY CO
Slide 11: OMNI: Customizable to All MIGS Categories in POAG
OMNI®: Customizable to All 6 MIGS Categories in POAG Low Risk of Hyphema Consistency of Efficacy Degree of Efficacy Represents estimated % of U.S. POAG TAM. The FDA granted an investigational device exemption authorizing our PRECISION RCT to assess the safety and effectiveness of a canaloplasty alon
Slide 12: Pieces in place to deliver the benefits of Standalone
Pieces in place to deliver the benefits of Standalone Leading label and most comprehensive treatment of conventional outflow pathway Significant investment in clinical trials, including 3 OMNI superiority RCTs versus existing treatments Glaucoma Clinical Consultants educating POAG community Signific
Slide 13: Development of Standalone MIGS Underway with OMNI
85% of glaucoma patients would be likely to get a Standalone intervention with OMNI if recommended by their doctor1 Development of Standalone MIGS Underway with OMNI Convert >5,600 MIGS-Trained Surgeons to OMNI Exceptional customer experience; hands-on training in dry labs and OR ~2,000 surgeons tra
Slide 14: Ongoing and Planned Trials
ROMEO (Completed) GEMINI (Completed) Ongoing and Planned Trials Goals 12-month multi-center retrospective real world study Elevated baseline IOP group: significant reduction in IOP and medications Controlled baseline IOP group: IOP controlled, significant reduction in medications Compelling and cons
Slide 15: Dry Eye Disease
—_— © Tearcare Sr — areueal O ae Dry EYE DISEASE e> fearCare
Slide 16: Dry Eye Disease and Meibomian Gland Dysfunction
Dry Eye Disease and Meibomian Gland Dysfunction MEIBOMIAN GLANDS Dry Eye Disease (DED) can be extremely painful and can lead to permanent cornea damage and vision impairment MGD is present in the vast majority of diagnosed dry eye cases, linked to many prominent demographic, medical and sociological
Slide 17: Our Solution: TearCare
Our Solution: TearCare® The Only Wearable Eyelid Technology designed to melt + remove meibomian gland obstructions Intuitive Design Designed for intuitive provider training and comfortable patient experience SmartLids™ are designed to conform to variable eyelid anatomy and heat glands to a proven te
Slide 18: TearCare Cleared by FDA December 2021
TearCare® Cleared by FDA December 2021 December 2021 Indication for Use “For the application of localized heat therapy in adult patients with evaporative DED due to MGD, when used in conjunction with manual expression of the meibomian glands” Considerable benefits from expanded indication for use Re
Slide 19: Support Patient Access Strategy with Expanded Label and RCT Clinical Data
1 Support Patient Access Strategy with Expanded Label and RCT Clinical Data vs. Rx Clinical and real-world data intended to support coverage, coding and payment Payor research: conducted eight 1:1s with medical directors from national and regional payors for feedback on our clinical programs (e.g.,
Slide 20: The OLYMPIA RCT
The OLYMPIA RCT OLYMPIA RCT (Completed) Head-to-head versus MGD device (LipiFlow®) Objective: To study effectiveness and safety of the TearCare System compared to LipiFlow in reducing the signs and symptoms of DED Prospective multi‐center (10 sites), randomized controlled, masked 135 total subjects
Slide 21: The SAHARA RCT
The SAHARA RCT Note: Clinical trials, including their design, endpoints and timing, are subject to change at the Company’s discretion. Initial results may include preliminary data and interim analyses that are subject to change. 2021 First patient, first visit 2Q 2021 2022 Enrollment completion expe
Slide 22: TearCare Controlled Release
TearCare® Controlled Release Executing a controlled release of TearCare with ~10 direct outside sales reps since April 2019 (expanded to ~20 3Q 2022) Successful patient-pay adoption Over 750 facilities added (through 6/30/2022); sizable base of steady reordering accounts Six consecutive quarters wit
Slide 23: New Product Overview
Delivering the Power of Sight NEW PRODUCT OVERVIEW
Slide 24: Our Product Development Process
Four fundamental requirements to deliver consistent, effective and safe outcomes for patients Our Product Development Process Comprehensive Understanding of Disease Physiology Analyze available clinical data, science and literature to achieve sound understanding of disease Address the Underlying Cau
Slide 25: Leverage Sight's Proven Development Expertise and Commercial Infrastructure
Our product development initiatives further leverage: An unparalleled clinical understanding of the underlying causes of glaucoma & dry eye A differentiated and efficient development process Ongoing and substantial investment in specialized Sales, Marketing, Clinical and Market Access resources that
Slide 26: Lead the Glaucoma and Dry Eye Disease Categories
Lead the Glaucoma and Dry Eye Disease Categories Portfolio will treat all severities of disease, ranging from mild to advanced Product suite will address the full continuum of care in tomorrow’s treatment paradigm + Portfolio will offer each of OTC, Sustained Rx, and Devices/Procedures Ability to tr
Slide 27: Offer a Comprehensive Portfolio of Six Products
Offer a Comprehensive Portfolio of Six Products SURGICAL GLAUCOMA PRODUCT DEVELOPMENT OVERVIEW 4. FDA-cleared canaloplasty followed by trabeculotomy 5. Canaloplasty alone IDE trial in process MILD TO MODERATE DISEASE In-office Injection of Sustained Release Pharmaceutical (Rx) 1 MILD TO MODERATE DIS
Slide 28: Offer a Comprehensive Portfolio of Four Products
Over-the-counter Artificial Tear With A Differentiated Lipid Layer Technology Dry Eye Disease Prescription Pharmaceutical Eyelid Ointment Office-Based Eyelid Procedure Home-Based Eyelid Device Treatment 1 2 4 Offer a Comprehensive Portfolio of Four Products DRY EYE DISEASE PRODUCT DEVELOPMENT OVERVI
Slide 29: Financial Overview
Delivering the Power of Sight FINANCIAL OVERVIEW
Slide 30: FY22 Highlights
FY22 Highlights Q2 Revenue: $17.2MM, +37% YoY Surgical Glaucoma: $15.9MM, +33% YoY Dry Eye: $1.3MM, +143% YoY Q2 Gross Margin: 84% Surgical Glaucoma: 88% Dry Eye: 41% Q2 YTD Revenue: $32.1MM, +52% YoY Surgical Glaucoma: $29.8MM, +48% YoY Dry Eye: $2.3MM, +124% YoY Q2 YTD Gross Margin: 82%** Surgical
Slide 31: Appendix
Delivering the Power of Sight APPENDIX
Slide 32: OMNI Clinical Timeline
OMNI® Clinical Timeline Note: Clinical trials, including their design, endpoints and timing, are subject to change at the Company’s discretion. Initial results may include preliminary data and interim analyses that are subject to change. 26